– 77% of early-stage relapsing-remitting multiple sclerosis (RRMS) patients who had not received prior treatment achieved no evidence of disease activity (NEDA) at two years – – Initiation of Ocrevus ...
TG Therapeutics, Inc.'s Briumvi, a treatment for multiple sclerosis, faces competition from Roche's Ocrevus, which has shown positive results in a Phase 3 trial. Briumvi's intravenous administration ...
– Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback